mTOR Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5142858-Each-of-1 | In Stock | ₹ 40,317.00 |
PIPA5142858 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 40,317.00
GST (18%): ₹ 7,257.06
Total Price: ₹ 47,574.06
Antigen
mTOR
Classification
Polyclonal
Conjugate
Unconjugated
Gene
MTOR
Gene Alias
2610315D21Rik; AI327068; angiopoietin-like factor CDT6; FK506 binding protein 12-rapamycin associated protein 1; FK506 binding protein 12-rapamycin associated protein 2; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; FKBP12-rapamycin complex-associated protein 1; FKBP-rapamycin associated protein; FKBP-rapamycin associated protein (FRAP); FKBP-rapamycin-associated protein FRAP; flat; FRAP; FRAP1; FRAP2; Mammalian target of rapamycin; mechanistic target of rapamycin; mechanistic target of rapamycin (serine/threonine kinase); mechanistic target of rapamycin kinase; Mtor; m-TOR; mTORC1; Raft1; Rapamycin and FKBP12 target 1; rapamycin and FKBP12 target-1 protein; rapamycin associated protein FRAP2; rapamycin target protein 1; RAPT1; serine/threonine-protein kinase mTOR; SKS
Host Species
Goat
Purification Method
Ammonium sulfate precipitation
Regulatory Status
RUO
Gene ID (Entrez)
2475
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Isotype
IgG
Applications
Immunocytochemistry
Concentration
0.5 mg/mL
Formulation
TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3
Gene Accession No.
P42345
Gene Symbols
MTOR
Immunogen
Peptide with sequence C-ETVDRLTESLDFTD.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human
Form
Liquid
Related Products
Description
- This antibody is tested in Peptide ELISA: antibody detection limit dilution 1:64,000
- FRAP1 (mTOR) is a serine/threonine kinase that plays a critical role in cellular growth and proliferation
- Perturbations in the mTOR/PI3-kinase/AKT pathway are associated with numerous forms of cancer
- FRAP1 is also the target of rapamycin and its analogues, which are currently used as immunosuppressants and cancer therapeutics
- Mutations affecting the gene results in Smith-Kingsmore syndrome.